Differential regulation of hepcidin in cancer and noncancer tissues and its clinical implications

다국어 초록 (Multilingual Abstract)

Hepcidin is a crucial peptide for regulating cellular iron efflux. Because iron is essential for cell survival, especially for highly active cells, such as tumor cells, it is imperative to understand how tumor cells manipulate hepcidin expression for their own metabolic needs. Studies suggest that hepcidin expression and regulation in tumor cells show important differences in comparison with those in non-tumorous cells. These differences should be investigated to develop new strategies to fight cancer cells. Manipulating hepcidin expression to starve cancer cells for iron may prove to be a new therapy in the anticancer arsenal.

참고문헌 (Reference)

1 Mleczko-Sanecka K, "Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling" 123 : 1574-1585, 2014

2 Yanagita M, "USAG-1: a bone morphogenetic protein antagonist abundantly expressed in the kidney" 316 : 490-500, 2004

3 Hentze MW, "Two to tango: regulation of mammalian iron metabolism" 142 : 24-38, 2010

4 Rosenwald A, "The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma" 346 : 1937-1947, 2002

5 Daniels TR, "The transferrin receptor and the targeted delivery of therapeutic agents against cancer" 1820 : 291-317, 2012

6 Tan TCH, "The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis" 32 : 1391-1399, 2012

7 Yuen H-F, "The prognostic significance of BMP-6 signaling in prostate cancer" 21 : 1436-1443, 2008

8 Bieniasz M, "The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients" 66 : 319-326, 2009

9 Fuqua BK, "The multicopper ferroxidase hephaestin enhances intestinal iron absorption in mice" 9 : e98792-, 2014

10 Langenfeld EM, "The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells" 24 : 1445-1454, 2003

11 Sugiyama H, "The expression of IL-6 and its related genes in acute leukemia" 21 : 49-52, 1996

12 Shao X, "The clinical value of hepcidin in breast cancer and its bone metastasis" 47 : 120-128, 2017

13 Crielaard BJ, "Targeting iron metabolism in drug discovery and delivery" 16 : 400-423, 2017

14 Callens C, "Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia" 207 : 731-750, 2010

15 Pusatcioglu CK, "Systemic and tumor level iron regulation in men with colorectal cancer: a case control study" 11 : 21-, 2014

16 Nachbaur DM, "Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters" 62 : 54-58, 1991

17 Cui R, "Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions" 38 : 545-550, 2014

18 Liu L, "SOSTDC1 is down-regulated in non-small cell lung cancer and contributes to cancer cell proliferation" 6 : 24-, 2016

19 Zhou Q, "SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways" 435 : 87-95, 2017

20 Clausen KA, "SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer" 129 : 737-746, 2011

21 Galli M, "Roneparstat (SST0001), an innovative heparanase (HPSE) inhibitor for multiple myeloma (MM) therapy: first in man study" 126 : 3246-, 2015

22 Girelli D, "Reduced serum hepcidin levels in patients with chronic hepatitis C" 51 : 845-852, 2009

23 Lee GT, "Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5Amediated BMP-6 induction" 110 : 1634-1644, 2014

24 Grijelmo C, "Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells" 19 : 1722-1732, 2007

25 Schonberg DL, "Preferential iron trafficking characterizes glioblastoma stem-like cells" 28 : 441-455, 2015

26 Gong J, "Pre-treatment of rats with ad-hepcidin prevents iron-induced oxidative stress in the brain" 90 : 126-132, 2016

27 Zhang F, "Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest" 283 : 33911-33918, 2008

28 Ciniselli CM, "Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone" 12 : 695-701, 2015

29 Deng H, "Overexpression of bone morphogenetic protein 4 enhances the invasiveness of Smad4-deficient human colorectal cancer cells" 281 : 220-231, 2009

30 Enns CA, "Neogenin interacts with matriptase-2 to facilitate hemojuvelin cleavage" 287 : 35104-35117, 2012

31 Zhao N, "Neogenin facilitates the induction of hepcidin expression by hemojuvelin in the liver" 291 : 12322-12335, 2016

32 "NOX-H94" Noxxon Pharma

33 Hsu H, "Mutations of p53 gene in hepatocellular-carcinoma (hcc) correlate with tumor progression and patient prognosis-a study of 138 patients with unifocal hcc" 4 : 1341-1347, 1994

34 Tan MGK, "Modulation of iron-regulatory genes in human hepatocellular carcinoma and its physiological consequences" 234 : 693-702, 2009

35 Brookes MJ, "Modulation of iron transport proteins in human colorectal carcinogenesis" 55 : 1449-1460, 2006

36 Tuhkanen H, "Matriptase-2 gene (TMPRSS6) variants associate with breast cancer survival, and reduced expression is related to triple-negative breast cancer" 133 : 2334-2340, 2013

37 Zhao N, "Low intracellular iron increases the stability of matriptase-2" 290 : 4432-4446, 2015

38 Voorneveld PW, "Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK" 147 : 196-208, 2014

39 Marques O, "Local iron homeostasis in the breast ductal carcinoma microenvironment" 16 : 187-, 2016

40 Xu G, "Lipocalin-2 induces cardiomyocyte apoptosis by increasing intracellular iron accumulation" 287 : 4808-4817, 2012

41 "LJPC-401" LaJolla Pharmaceutical

42 Krause A, "LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity" 480 : 147-150, 2000

43 Chanvorachote P, "Iron induces cancer stem cells and aggressive phenotypes in human lung cancer cells" 310 : C728-C739, 2016

44 Urano S, "Iron depletion enhances the effect of sorafenib in hepatocarcinoma" 17 : 648-656, 2016

45 Torti SV, "Iron and cancer: more ore to be mined" 13 : 342-355, 2013

46 Sharma S, "Involvement of hepcidin in the anemia of multiple myeloma" 14 : 3262-3267, 2008

47 Wrighting DM, "Interleukin-6 induces hepcidin expression through STAT3" 108 : 3204-3209, 2006

48 Ara T, "Interleukin-6 in bone metastasis and cancer progression" 46 : 1223-1231, 2010

49 Egler RA, "Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma" 14 : 7028-7034, 2008

50 Yeh K, "Interactions between ferroportin and hephaestin in rat enterocytes are reduced after iron ingestion" 141 : 292-299, 2011

51 Goodnough JB, "Inhibition of hepcidin transcription by growth factors" 56 : 291-299, 2012

52 Owens P, "Inhibition of BMP signaling suppresses metastasis in mammary cancer" 34 : 2437-2449, 2015

53 Coussens LM, "Inflammation and cancer" 420 : 860-867, 2002

54 Urrutia P, "Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells" 126 : 541-549, 2013

55 Kamai T, "Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma" 9 : 270-, 2009

56 Chen H, "Increased hepcidin in transferrin-treated thalassemic mice correlates with increased liver BMP2 expression and decreased hepatocyte ERK activation" 101 : 297-308, 2016

57 Chen Q, "Increased hepcidin expression in non-small cell lung cancer tissue and serum is associated with clinical stage" 5 : 14-24, 2014

58 Ward DG, "Increased hepcidin expression in colorectal carcinogenesis" 14 : 1339-1345, 2008

59 Masuda H, "Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer" 54 : 268-274, 2003

60 Pechlaner R, "Inadequate hepcidin serum concentrations predict incident type 2 diabetes mellitus" 32 : 187-192, 2016

61 Maes K, "In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2" 116 : 3635-3644, 2010

62 Kautz L, "Identification of erythroferrone as an erythroid regulator of iron metabolism" 46 : 678-684, 2014

63 Schmidt-Arras D, "IL-6 pathway in the liver: from physiopathology to therapy" 64 : 1403-1415, 2016

64 He Y, "Hypermethylation leads to bone morphogenetic protein 6 downregulation in hepatocellular carcinoma" 9 : e87994-, 2014

65 Tanno T, "Hepcidin, anaemia, and prostate cancer" 107 : 678-679, 2011

66 Weizer-Stern O, "Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53" 138 : 253-262, 2007

67 Du F, "Hepcidin suppresses brain iron accumulation by downregulating iron transport proteins in ironoverloaded rats" 52 : 101-114, 2015

68 Tesfay L, "Hepcidin regulation in prostate and its disruption in prostate cancer" 75 : 2254-2263, 2015

69 Zhou Y-F, "Hepcidin protects neuron from hemin-mediated injury by reducing iron" 8 : 332-, 2017

70 Santini V, "Hepcidin levels and their determinants in different types of myelodysplastic syndromes" 6 : e23109-, 2011

71 Ciccarelli BT, "Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenstrom's macroglobulinemia" 11 : 160-163, 2011

72 Bridle KR, "Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease" 30 : 106-112, 2006

73 Han CY, "Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt" 7 : 13817-, 2016

74 Cheng P-P, "Hepcidin expression in patients with acute leukaemia" 42 : 517-525, 2012

75 Du F, "Hepcidin directly inhibits transferrin receptor 1 expression in astrocytes via a cyclic AMP-protein kinase a pathway" 59 : 936-945, 2011

76 Poli M, "Hepcidin antagonists for potential treatments of disorders with hepcidin excess" 5 : 86-, 2014

77 Ganz T, "Hepcidin and iron homeostasis" 1823 : 1434-1443, 2012

78 Kessler SM, "Hepatic hepcidin expression is decreased in cirrhosis and HCC" 62 : 977-979, 2015

79 Poli M, "Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo" 117 : 997-1004, 2011

80 Niederkofler V, "Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload" 115 : 2180-2186, 2005

81 Poli M, "Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo" 123 : 1564-1573, 2014

82 McCarthy RC, "Glial cell ceruloplasmin and hepcidin differentially regulate iron efflux from brain microvascular endothelial cells" 9 : e89003-, 2014

83 Feng Q, "Ferritin upregulates hepatic expression of bone morphogenetic protein 6 and hepcidin in mice" 302 : G1397-G1404, 2012

84 Yang DC, "Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer" 21 : 541-549, 2001

85 Hanninen MM, "Expression of iron-related genes in human brain and brain tumors" 10 : 36-, 2009

86 Tseng H-H, "Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications" 135 : 1413-1420, 2009

87 Langenfeld EM, "Expression of bone morphogenetic proteins in human lung carcinomas" 80 : 1028-1032, 2005

88 Chen J, "Expression of bone morphogenetic protein 7 in lung cancer and its biological impact on lung cancer cells" 30 : 1113-1120, 2010

89 Pauk M, "Exogenous BMP7 corrects plasma iron overload and bone loss in $Bmp6^{-/-}$ mice" 39 : 161-172, 2015

90 Canali S, "Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice" 129 : 405-414, 2017

91 Maegdefrau U, "Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma" 91 : 1615-1623, 2011

92 Zhang S, "Disordered hepcidin-ferroportin signaling promotes breast cancer growth" 26 : 2539-2550, 2014

93 Dayani PN, "Desferoxamine (DFO)-mediated iron chelation: rationale for a novel approach to therapy for brain cancer" 67 : 367-377, 2004

94 Terada N, "Definition of the roles for iron and essential fatty acids in cell cycle progression of normal human T lymphocytes" 204 : 260-267, 1993

95 Valdes PA, "Deferoxamine iron chelation increases ${\delta}$-aminolevulinic acid induced protoporphyrin IX in xenograft glioma model" 86 : 471-475, 2010

96 Gu Z, "Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation" 75 : 2211-2221, 2015

97 Wallace DF, "Combined deletion of Hfe and transferrin receptor 2 in mice leads to marked dysregulation of hepcidin and iron overload" 50 : 1992-2000, 2009

98 Motoyama K, "Clinical significance of BMP7 in human colorectal cancer" 15 : 1530-1537, 2008

99 Lehtihet M, "Circulating hepcidin-25 is reduced by endogenous estrogen in humans" 11 : e0148802-, 2016

100 Musci G, "Ceruloplasmin-ferroportin system of iron traffic in vertebrates" 5 : 204-215, 2014

101 Truksa J, "Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6" 103 : 10289-10293, 2006

102 Barnes J, "Bone morphogenetic protein-6 expression in normal and malignant prostate" 13 : 337-343, 1995

103 Deng H, "Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells" 313 : 1033-1044, 2007

104 Wiley DM, "Bone morphogenetic protein functions as a contextdependent angiogenic cue in vertebrates" 22 : 1012-1018, 2011

105 Morrissey C, "Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment" 12 : 192-205, 2010

106 Zhang T, "Bone morphogenetic protein 7 is associated with the nodal invasion of colon cancer" 11 : 1707-1712, 2016

107 Buijs JT, "Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer" 67 : 8742-8751, 2007

108 Vishnubalaji R, "Bone morphogenetic protein 2 (BMP2) induces growth suppression and enhances chemosensitivity of human colon cancer cells" 16 : 77-, 2016

109 Haudenschild DR, "Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer" 64 : 8276-8284, 2004

110 Andriopoulos B Jr, "BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism" 41 : 482-487, 2009

111 Hu F, "BMP-6 inhibits cell proliferation by targeting microRNA-192 in breast cancer" 1832 : 2379-2390, 2013

112 Cassinelli G, "Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models" 85 : 1424-1432, 2013

113 Song L, "Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer" 9 : 974-982, 2014

114 Kovac S, "Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels" 101 : e173-e176, 2016

115 Tisi MC, "Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin" 55 : 270-275, 2014

116 Yao L-Q, "Analysis of the role of the BMP7-Smad4-Id2 signaling pathway in SW480 colorectal carcinoma cells" 4 : 627-631, 2011

117 Lakhal-Littleton S, "An essential cell-autonomous role for hepcidin in cardiac iron homeostasis" 5 : e19804-, 2016

118 Blish KR, "A human bone morphogenetic protein antagonist is down-regulated in renal cancer" 19 : 457-464, 2008

119 Vadhan-Raj S, "A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia" 10 : 73-, 2017